Product Description
ANV600 is a novel bispecific compound, comprising an anti-IL-2 antibody/IL-2 fusion protein and a proprietary hPD-1 binding moiety for specific delivery of IL-2 to tumor antigen experienced PD-1+ T cells. ANV600 treatment leads to a dose-dependent increase of intratumoral, stem-like and cytotoxic PD-1+T cells in mice harboring B16F10 and MC38 subcutaneous tumors and markedly retards tumor growth. (Sourced from: https://anaveon.com/news/anaveon-announces-presentation-of-a-novel-development-compound-at-the-2023-american-association-for-cancer-research-annual-meeting/)
Mechanisms of Action: PD-1 Inhibitor,IL2 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Anaveon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Germany, Spain, Switzerland
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ANV600-001 | P2 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2027-10-31 |
|
| EXPAND-1 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-10-01 |